Lineage Cell Therapeutics (LCTX) Net Cash Flow (2010 - 2026)

Lineage Cell Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 334.98% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$12.3 million (down 385.55% YoY), while the FY2025 annual figure was -$5.4 million, down 151.89% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.8 million, down from $167000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $22.4 million in Q1 2022, with the low at -$45.4 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$1.8 million (2025), against an average of -$1.1 million.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 3695.32% in 2022, then jumped 385.8% in 2024.
• Lineage Cell Therapeutics' Net Cash Flow stood at -$13.3 million in 2022, then soared by 127.93% to $3.7 million in 2023, then surged by 385.8% to $18.0 million in 2024, then slumped by 99.07% to $167000.0 in 2025, then sank by 3000.0% to -$4.8 million in 2026.
• Business Quant data shows LCTX's Net Cash Flow at -$4.8 million in Q1 2026, $167000.0 in Q4 2025, and -$1.8 million in Q3 2025.